Welcome to our dedicated page for Cyanotech SEC filings (Ticker: CYAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cyanotech Corporation’s numbers don’t come from factories; they arise from billable hours, audit engagements and tax strategies across Spain. When you open a Cyanotech annual report 10-K, you’re not just skimming financials—you’re dissecting how a Madrid accounting firm turns regulatory expertise into revenue. That’s why many professionals search for “Cyanotech SEC filings explained simply.”
Stock Titan’s AI distills each document so you can move straight to insight. Want the Cyanotech quarterly earnings report 10-Q filing without reading footnote 47? Our platform delivers concise summaries, variance analysis and trend charts. Curious about partner incentives? The Cyanotech proxy statement executive compensation section is highlighted, and adjustments are flagged. We even surface Cyanotech 8-K material events explained—from major client wins to disciplinary actions—minutes after they appear on EDGAR.
Real-time tracking matters when governance and reputation drive value. Instantly monitor Cyanotech insider trading Form 4 transactions or set alerts for Cyanotech Form 4 insider transactions real-time; see which senior partners are buying shares. Use AI-generated tags like “audit backlog” or “client concentration risk” to navigate the Cyanotech annual report 10-K simplified. Typical use cases include:
- Benchmark advisory-versus-audit margins via Cyanotech earnings report filing analysis
- Compare quarter-over-quarter cash flows without waiting for earnings calls
- Spot remuneration shifts through Cyanotech executive stock transactions Form 4
Whether you’re a portfolio manager understanding Cyanotech SEC documents with AI or a compliance officer validating disclosures, every filing type—from 10-K and 10-Q to 4 and 8-K—is indexed, summarised and searchable. Complex professional-services disclosures, now clear and timely.
Cyanotech Corporation (CYAN) filed its quarterly report for the period ended September 30, 2025. Net sales rose to $6.976 million from $5.845 million, driven by stronger packaged and bulk astaxanthin and spirulina demand. Gross profit improved to $2.393 million with margin at 34.3% versus 25.3% a year ago as higher production volumes lowered unit costs and select price increases aided mix.
Operating expenses fell to $2.203 million, producing operating income of $190,000 (prior year loss of $975,000). After interest expense of $189,000, net income was $1,000, or $0.00 per share. For the six months, net sales were $12.797 million and net loss was $925,000.
Liquidity remains tight: cash was $649,000 and working capital $39,000. Debt included $370,000 on the 2023 bank term loan (maturing March 31, 2026), $2.809 million on the 2012 loan (amortizing to August 2032), and a related-party revolver with $4.200 million outstanding (capacity $4.600 million, expiring April 12, 2027). The company notes substantial doubt about continuing as a going concern, citing prior covenant noncompliance (waived) and a bank freeze on further line advances. As of
Jennifer A.S. Miyashiro, an officer of Cyanotech Corp (CYAN), was granted 50,000 stock options on 09/12/2025. The options carry an exercise price of $0.29 and expire on 09/12/2035. Following the grant, Ms. Miyashiro beneficially owns 50,000 underlying shares directly. The options vest in three tranches: 16,666 shares on 09/12/2026, 16,667 shares on 09/12/2027 and 16,667 shares on 09/12/2028, each subject to continued service with Cyanotech on the vesting date. The Form 4 was signed by Linda Tanoai by power of attorney on 09/15/2025.
Cyanotech Corp (CYAN) disclosure: Jennifer A.S. Miyashiro is reported as an officer (Chief Financial Officer, Vice President Finance & Administration, Treasurer) of the company and the filing is an initial Form 3 disclosing beneficial ownership. The filing states that the reporting person does not beneficially own any securities of the issuer as reported in this initial statement.
FAQ
What is the current stock price of Cyanotech (CYAN)?
What is the market cap of Cyanotech (CYAN)?
